Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8 Ịdị ọcha>98.0% (GC) Ụlọ ọrụ etiti Lenvatinib Mesylate

Nkọwa dị mkpirikpi:

Aha Chemical: Methyl 4-Amino-2-Methoxybenzoate

Ọkụ: 27492-84-8

Dị ọcha:> 98.0% (GC)

Ọdịdị: White to Off-White Powder or Crystals

Ọkara nke Lenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com


Nkọwa ngwaahịa

Ngwaahịa ndị emetụtara

Mkpado ngwaahịa

Nkọwa:

Njirimara kemịkalụ:

Aha Chemical Methyl 4-Amino-2-Methoxybenzoate
Ụdị okwu 4-Amino-2-Methoxybenzoic Acid Methyl Ester;Methyl 4-Amino-o-Anisate;4-Amino-o-Anisic Acid Methyl Ester
Nọmba CAS 27492-84-8
Nọmba CAT RF-PI1974
Ọnọdụ Ahịa N'ọkwa, Mpụta Ihe ruru Tọn
Usoro ihe omimi C9H11NO3
Ibu molekụla 181.19
Njupụta 1.179±0.060 g/cm3
Ụdị Ruifu Chemical

Nkọwapụta:

Ihe Nkọwapụta
Ọdịdị Ọcha ka Gbanyụọ-Ọcha ntụ ntụ ma ọ bụ kristal
Ụzọ ịdị ọcha / nyocha > 98.0% (GC)
Ụzọ ịdị ọcha / nyocha 97.5 ~ 102.5 (Titration na-adịghị mma)
Ebe Na-agbaze 157.0 ~ 161.0 ℃
Ọnwụ na ihicha <1.00%
Mgbakọta adịghị ọcha <2.0%
Spectrum infrared Dabara na Ọdịdị
Ọnụ ego nke Proton NMR Spectrum Dabara na Ọdịdị
Nlele ọkọlọtọ Standardkpụrụ ụlọ ọrụ
Ojiji Ndị etiti Lenvatinib Mesylate (CAS: 857890-39-2)

Ngwungwu & Nchekwa:

ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ

Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri

Uru:

1

Ajụjụ:

Ngwa:

Enwere ike iji Methyl 4-Amino-2-Methoxybenzoate (CAS: 27492-84-8) mee ihe dị ka etiti nke Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib bụ ọgwụ cancer thyroid nke Eisai Corporation nke Japan mepụtara (koodu: E7080), bụ nke onye na-emechi ọnụ nke tyrosine kinase (RTK) nke na-emechi ọnụ ma nwee ike igbochi ọrụ kinase nke vascular endothelial growth factor (VEGF) ndị na-anabata VEGFR1. FLT1), VEGFR2 (KDR), na VEGFR3 (FLT4).Lenvatinib nwekwara ike igbochi itinye aka nke RTK ndị ọzọ na angiogenesis pathological, uto tumor, na ọganihu cancer ma e wezụga maka ọrụ cellular ha na-emekarị gụnyere fibroblast growth factor (FGF) ndị na-anabata FGFR1, 2, 3, na 4;ihe nnabata ihe uto nke platelet (PDGFR [alpha]), KIT, na RET.[Ngosipụta]: Lenvatinib dị mma maka ọgwụgwọ ndị ọrịa nke ọrịa cancer thyroid nke nlọghachi azụ mpaghara ma ọ bụ ụdị metastasis, ụdị ọganihu na redioactive iodine-refractory dị iche iche.Na February 13, 2015, US FDA kwadoro ọgwụ anticancer Lenvatinib maka ọgwụgwọ ọrịa cancer thyroid.Lenvatinib bụ onye na-egbochi enzyme multi-ezubere iche, na-enwe ike igbochi VEGFR2 na VEGFR3 (vaskụla endothelial growth factor receptor).Aha ahia nke Lenvatinib bụ Lenvima.Na May 20, 2015, Ụlọ Ọrụ Na-ahụ Maka Ọgwụ na Europe (EMA) kwadoro Lenvatinib maka ọgwụgwọ nke mkparị, nke dị na mpaghara ma ọ bụ metastatic dị iche iche (papillary, follicular, Hurthle ụdị) ọrịa cancer thyroid (DTC).N'ime ule ahụ, oge ndụ nke etiti maka ndị ọrịa nwere redioactive iodine refractory DTC nke a na-emeso Lenvatinib bụ ọnwa 18 ebe uru maka ndị ọrịa na-ewere placebo bụ nanị ọnwa 3.

Dee ozi gị ebe a ziga anyị ya